|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||16.40 - 16.40|
|52-week range||11.96 - 31.74|
|Beta (5Y monthly)||0.83|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||0.92 (5.63%)|
|Ex-dividend date||11 May 2023|
|1y target est||N/A|
Royal Philips (NYSE: PHG) is promising a turnaround from its bottom-line woes, which began with one of the largest medical devices recalls in recent history. Two major factors explain the softness in Royal Philips' 2022 results: the ever-expanding recall of its subsidiary Philips Respironics' ventilators and sleep apnea masks, and continuing supply chain problems in the wake of the COVID-19 pandemic. There may be little the Netherlands-based company can do about component shortages, but the high-profile issues it faces due to defective sound abatement (noise reduction) foam in its breathing devices have no clear end.
It's been a good week for Koninklijke Philips N.V. ( AMS:PHIA ) shareholders, because the company has just released its...
Koninklijke Philips ( AMS:PHIA ) Full Year 2022 Results Key Financial Results Revenue: €17.8b (up 3.9% from FY 2021...